Advertisement

U.S. markets open in 2 hours 5 minutes

S&P Futures
3,771.00
-50.25(-1.32%)
Dow Futures
30,654.00
-345.00(-1.11%)
Nasdaq Futures
11,512.25
-178.75(-1.53%)
Russell 2000 Futures
1,694.70
-26.70(-1.55%)
Crude Oil
109.26
-0.52(-0.47%)
Gold
1,812.00
-5.50(-0.30%)

Advertisement

Nevro Corp. (NVRO)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

45.97

-0.41

(-0.88%)

At close: 04:00PM EDT

45.97

-0.01

(-0.02%)

After hours:

04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Engulfing Line (Bearish)

View all chart patterns

Performance Outlook

Previous Close	46.38
Open	46.47
Bid	0.00 x 900
Ask	48.02 x 3000
Day's Range	44.59 - 46.47
52 Week Range	39.41 - 168.19
Volume	245,328
Avg. Volume	568,508

Market Cap	1.621B
Beta (5Y Monthly)	1.09
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NVRO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Nevro Corp.
Analyst Report: LivaNova PLCU.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management segment. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Rating
Fair Value
Economic Moat
6 days agoMorningstar